Treatment of hypertension in adults with diabetes

Carlos Arauz-Pacheo, Marian A. Parrott, Philip Raskin

Research output: Contribution to journalArticle

289 Citations (Scopus)

Abstract

There is a strong epidemiological connection between hypertension in diabetes and adverse outcomes of diabetes. Clinical trials demonstrate the efficacy of drug therapy versus placebo in reducing these outcomes and in setting an aggressive blood pressure-lowering target of < 130/80 mmHg. It is very clear that many people will require three or more drugs to achieve the recommended target. Achievement of the target blood pressure goal with a regimen that does not produce burdensome side effects and is at reasonable cost to the patient is probably more important than the specific drug strategy. Because many studies demonstrate the benefits of ACE inhibitors on multiple adverse outcomes in patients with diabetes, including both macrovascular and microvascular complications, in patients with either mild or more severe hypertension and in both type 1 and type 2 diabetes, the established practice of choosing an ACE inhibitor as the first-line agent in most patients with diabetes is reasonable. In patients with microalbuminemia or clinical nephropathy, both ACE inhibitors (type 1 and type 2 patients) and ARBs (type 2 patients) are considered first-line therapy for the prevention of and progression of nephropathy. However, other strategies including diuretic and β-blocker-based therapy are also supported by evidence. Because of lingering concerns about the lower effectiveness of DCCBs (compared with ACE inhibitors, ARBs, β-blockers, or diuretics) in decreasing coronary events and heart failure and in reducing progression of renal disease in diabetes, these agents should be used as second-line drugs for patients who cannot tolerate the other preferred classes or who require additional agents to achieve the target blood pressure. Other classes, including α-blockers, may be used under specific indications (such as symptoms of BPH for α-blockers) or other agents have failed to control the blood pressure or have unacceptable side effects. Blood pressure, orthostatic changes, renal function, and serum potassium should be monitored at appropriate intervals. Treatment decisions should be individualized based on the clinical characteristics of the patient, including comorbidities as well as tolerability, personal preferences, and cost.

Original languageEnglish (US)
JournalDiabetes Care
Volume26
Issue numberSUPPL. 1
StatePublished - Jan 1 2003

Fingerprint

Hypertension
Angiotensin-Converting Enzyme Inhibitors
Blood Pressure
Therapeutics
Diuretics
Pharmaceutical Preparations
Kidney
Costs and Cost Analysis
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Disease Progression
Comorbidity
Potassium
Heart Failure
Placebos
Clinical Trials
Drug Therapy
Serum

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Arauz-Pacheo, C., Parrott, M. A., & Raskin, P. (2003). Treatment of hypertension in adults with diabetes. Diabetes Care, 26(SUPPL. 1).

Treatment of hypertension in adults with diabetes. / Arauz-Pacheo, Carlos; Parrott, Marian A.; Raskin, Philip.

In: Diabetes Care, Vol. 26, No. SUPPL. 1, 01.01.2003.

Research output: Contribution to journalArticle

Arauz-Pacheo, C, Parrott, MA & Raskin, P 2003, 'Treatment of hypertension in adults with diabetes', Diabetes Care, vol. 26, no. SUPPL. 1.
Arauz-Pacheo C, Parrott MA, Raskin P. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003 Jan 1;26(SUPPL. 1).
Arauz-Pacheo, Carlos ; Parrott, Marian A. ; Raskin, Philip. / Treatment of hypertension in adults with diabetes. In: Diabetes Care. 2003 ; Vol. 26, No. SUPPL. 1.
@article{4d2944c7b9394a44bf34c260bef523f1,
title = "Treatment of hypertension in adults with diabetes",
abstract = "There is a strong epidemiological connection between hypertension in diabetes and adverse outcomes of diabetes. Clinical trials demonstrate the efficacy of drug therapy versus placebo in reducing these outcomes and in setting an aggressive blood pressure-lowering target of < 130/80 mmHg. It is very clear that many people will require three or more drugs to achieve the recommended target. Achievement of the target blood pressure goal with a regimen that does not produce burdensome side effects and is at reasonable cost to the patient is probably more important than the specific drug strategy. Because many studies demonstrate the benefits of ACE inhibitors on multiple adverse outcomes in patients with diabetes, including both macrovascular and microvascular complications, in patients with either mild or more severe hypertension and in both type 1 and type 2 diabetes, the established practice of choosing an ACE inhibitor as the first-line agent in most patients with diabetes is reasonable. In patients with microalbuminemia or clinical nephropathy, both ACE inhibitors (type 1 and type 2 patients) and ARBs (type 2 patients) are considered first-line therapy for the prevention of and progression of nephropathy. However, other strategies including diuretic and β-blocker-based therapy are also supported by evidence. Because of lingering concerns about the lower effectiveness of DCCBs (compared with ACE inhibitors, ARBs, β-blockers, or diuretics) in decreasing coronary events and heart failure and in reducing progression of renal disease in diabetes, these agents should be used as second-line drugs for patients who cannot tolerate the other preferred classes or who require additional agents to achieve the target blood pressure. Other classes, including α-blockers, may be used under specific indications (such as symptoms of BPH for α-blockers) or other agents have failed to control the blood pressure or have unacceptable side effects. Blood pressure, orthostatic changes, renal function, and serum potassium should be monitored at appropriate intervals. Treatment decisions should be individualized based on the clinical characteristics of the patient, including comorbidities as well as tolerability, personal preferences, and cost.",
author = "Carlos Arauz-Pacheo and Parrott, {Marian A.} and Philip Raskin",
year = "2003",
month = "1",
day = "1",
language = "English (US)",
volume = "26",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Treatment of hypertension in adults with diabetes

AU - Arauz-Pacheo, Carlos

AU - Parrott, Marian A.

AU - Raskin, Philip

PY - 2003/1/1

Y1 - 2003/1/1

N2 - There is a strong epidemiological connection between hypertension in diabetes and adverse outcomes of diabetes. Clinical trials demonstrate the efficacy of drug therapy versus placebo in reducing these outcomes and in setting an aggressive blood pressure-lowering target of < 130/80 mmHg. It is very clear that many people will require three or more drugs to achieve the recommended target. Achievement of the target blood pressure goal with a regimen that does not produce burdensome side effects and is at reasonable cost to the patient is probably more important than the specific drug strategy. Because many studies demonstrate the benefits of ACE inhibitors on multiple adverse outcomes in patients with diabetes, including both macrovascular and microvascular complications, in patients with either mild or more severe hypertension and in both type 1 and type 2 diabetes, the established practice of choosing an ACE inhibitor as the first-line agent in most patients with diabetes is reasonable. In patients with microalbuminemia or clinical nephropathy, both ACE inhibitors (type 1 and type 2 patients) and ARBs (type 2 patients) are considered first-line therapy for the prevention of and progression of nephropathy. However, other strategies including diuretic and β-blocker-based therapy are also supported by evidence. Because of lingering concerns about the lower effectiveness of DCCBs (compared with ACE inhibitors, ARBs, β-blockers, or diuretics) in decreasing coronary events and heart failure and in reducing progression of renal disease in diabetes, these agents should be used as second-line drugs for patients who cannot tolerate the other preferred classes or who require additional agents to achieve the target blood pressure. Other classes, including α-blockers, may be used under specific indications (such as symptoms of BPH for α-blockers) or other agents have failed to control the blood pressure or have unacceptable side effects. Blood pressure, orthostatic changes, renal function, and serum potassium should be monitored at appropriate intervals. Treatment decisions should be individualized based on the clinical characteristics of the patient, including comorbidities as well as tolerability, personal preferences, and cost.

AB - There is a strong epidemiological connection between hypertension in diabetes and adverse outcomes of diabetes. Clinical trials demonstrate the efficacy of drug therapy versus placebo in reducing these outcomes and in setting an aggressive blood pressure-lowering target of < 130/80 mmHg. It is very clear that many people will require three or more drugs to achieve the recommended target. Achievement of the target blood pressure goal with a regimen that does not produce burdensome side effects and is at reasonable cost to the patient is probably more important than the specific drug strategy. Because many studies demonstrate the benefits of ACE inhibitors on multiple adverse outcomes in patients with diabetes, including both macrovascular and microvascular complications, in patients with either mild or more severe hypertension and in both type 1 and type 2 diabetes, the established practice of choosing an ACE inhibitor as the first-line agent in most patients with diabetes is reasonable. In patients with microalbuminemia or clinical nephropathy, both ACE inhibitors (type 1 and type 2 patients) and ARBs (type 2 patients) are considered first-line therapy for the prevention of and progression of nephropathy. However, other strategies including diuretic and β-blocker-based therapy are also supported by evidence. Because of lingering concerns about the lower effectiveness of DCCBs (compared with ACE inhibitors, ARBs, β-blockers, or diuretics) in decreasing coronary events and heart failure and in reducing progression of renal disease in diabetes, these agents should be used as second-line drugs for patients who cannot tolerate the other preferred classes or who require additional agents to achieve the target blood pressure. Other classes, including α-blockers, may be used under specific indications (such as symptoms of BPH for α-blockers) or other agents have failed to control the blood pressure or have unacceptable side effects. Blood pressure, orthostatic changes, renal function, and serum potassium should be monitored at appropriate intervals. Treatment decisions should be individualized based on the clinical characteristics of the patient, including comorbidities as well as tolerability, personal preferences, and cost.

UR - http://www.scopus.com/inward/record.url?scp=0037898667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037898667&partnerID=8YFLogxK

M3 - Article

C2 - 12502624

AN - SCOPUS:0037898667

VL - 26

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - SUPPL. 1

ER -